Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 82

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 3
Chunk 82
---
.0 million
or more or controlled by any exempt entity (exempt entity is, entity which is exempted from income tax). Our aggregated turnover is less
than A$20.0 million, so we anticipate being entitled to a claim of 43.5% refundable tax offset for costs relating to eligible R& D
activities for our most recently completed fiscal year and our current fiscal year.

We have incurred net losses
since inception and expect to incur substantial and increasing losses for the next several years as we expand our research and development
activities and move our drug candidate into later stages of development. The process of carrying out the development of our drug candidates
to later stages of development may require significant additional research and development expenditures, including pre-clinical testing
and clinical trials, as well as for obtaining regulatory approval. To date, we have funded our operations primarily through the sale of
equity securities, proceeds from the exercise of options and interest income.

A. Operating Results

Results of Operations

Comparison of fiscal year ended June 30, 2025 to June 30, 2024

The following table summarizes our results from
operations for the years ended June 30, 2025 and 2024, together with the changes in those items in dollars set forth our results of operations
in Australian dollars for the fiscal years ended June 30, 2025 and June 30, 2024.

                                                                 Fiscal year ended June 30                                   
                                                                                      2025                                   
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
                                                                                        A$                                   
  Revenue from contracts with customers                                          3,633,422          299,228       3,334,194  
  Cost of sales                                                                 (3,594,146                -      (3,594,146  
  Other income                                                                  10,256,740        1,343,062       8,913,678  
  Other losses                                                                    (351,646       (1,226,108         874,462  
  Loss on movement in contingent consideration                                  (4,069,680       (8,860,358       4,790,678  
  General and administrative expenses                                          (14,638,013      (13,039,246      (1,598,767  
  Research and development                                                     (27,515,194      (23,086,267      (4,428,927  
  Share-based payments                                                          (